webinar series
Mineralocorticoid Receptor Antagonist in the Art of Managing HFpEF
A to Z of CV Pharmacotherapy: Webinar Series
Antagonist in the Art of Managing HFpEF
This webinar was held live on Wednesday 14th May 2025 at 12:00 pm BST.
Organised by the International Society of Cardiovascular Pharmacotherapy (ISCP), this free, 1-hour session provided healthcare professionals with a comprehensive overview of the evolving role of MRAs in HFmEF and HFpEF.
Non-steroidal MRAs, such as finerenone, have garnered particular attention due to their more selective mechanism of action, which may offer advantages over traditional steroidal MRAs like spironolactone and eplerenone. Data from pivotal trials, including FIDELIO-DKD, FIGARO-DKD, and FINEARTS-HF, have provided compelling evidence that MRAs contribute to significant reductions in the combined endpoints of cardiovascular death and heart failure hospitalizations in patients with HFmEF and HFpEF.
This webinar provides a comprehensive overview of the evolving role of MRAs in HFmEF and HFpEF, highlighting:
The pathophysiology of mineralocorticoid receptor activation and its contribution to inflammation, fibrosis, and volume overload in heart failure.
Key clinical trials and meta-analyses that support the expanded use of MRAs beyond HFrEF.
Practical considerations for selecting appropriate patients for MRA therapy, with a focus on safety, renal function, and hyperkalemia risk mitigation.
Future directions in MRA research and its integration into evolving heart failure treatment guidelines.
This programme was supported by an unrestricted educational grant by Bayer.
Learning Objectives
✅ Evaluate the pathophysiologic role of mineralocorticoid receptor activation in heart failure and its implications for HFmEF/HFpEF management.
✅ Analyze the latest clinical evidence supporting the use of MRAs in HFmEF/HFpEF, including recent trial data and guideline recommendations.
✅ Assess the safety profile of MRAs, including the risks of hyperkalemia, renal dysfunction, and other adverse effects in the HFmEF/HFpEF population.
✅ Identify appropriate patients for MRA therapy, considering comorbid conditions, renal function, and serum potassium levels.
✅ Develop individualized therapeutic plans incorporating MRAs into the broader management strategy for HFmEF/HFpEF, including combination therapy approaches and monitoring strategies.
The Faculty
Dr Vebiona Kartini - Moderator
Dr Vebiona Kartini Prima Putri moderated the session from Indonesia, guiding discussions with clinical clarity and regional insight.
Dr Craig Beavers - Speaker
Joining from the USA, Dr Craig Beavers presented on integrating MRAs into real-world heart failure treatment practices.
Dr Bassam Atallah - Panelist
Dr Bassam Atallah brought perspectives from the UAE, focusing on patient selection and practical application of MRAs in HFpEF management.
Dr Lorenz van der Linden - Panelist
From Belgium, Dr Lorenz Van der Linden examined trial data and future directions for non-steroidal MRAs in heart failure care.
Performed by:
Moderator
Vebiona Kartini Prima Putri
Speaker
Craig Beavers
Panelist
Bassam Atallah
Panelist
Lorenz van der Linden
restricted content
ISCP Members Only
Access to the e-Learning and Experts sections is available to ISCP Members only. Already a Member? Log in Not yet a Member? Visit our Registration page for details of how to join the ISCP and learn more about the benefits of being a part.